Open AccessCardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents
Author(s) -
Bruce P. Smith,
Matthew A. Warner,
Nafisseh S. Warner,
Andrew C. Hanson,
Mark M. Smith,
Charanjit S. Rihal,
Rajiv Gulati,
Malcolm R. Bell,
Gregory A. Nuttall
Publication year - 2019
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0000000000003408
Subject(s) - medicine , mace , percutaneous coronary intervention , conventional pci , aspirin , odds ratio , incidence (geometry) , surgery , confidence interval , clopidogrel , cardiology , myocardial infarction , physics , optics
Noncardiac surgery (NCS) following percutaneous coronary intervention (PCI) with stenting is sometimes associated with major adverse cardiac events (MACEs). Second-generation drug-eluting stents (DES) were developed to decrease the incidence of MACE seen with bare metal and first-generation DES.